Abstract: Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells. Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.

Abstract: This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.

Abstract: Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.

Abstract: Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.

Abstract: A population of improved tumor infiltrating lymphocytes (TILs). These TILs have increased metabolic activity (MA), and increased therapeutic efficacy for cancer treatment, allowing applying reduced cell doses to a subject in need thereof. Further disclosed are methods for selecting a population of TILs with increased metabolic activity, methods for producing, and methods for using said TILs.

Abstract: There is provided a method of concentrating functional biological components within a liquid suspension, the method comprising: providing a system comprising an ultrafiltration/concentration unit (UCU), the UCU comprising a first chamber for receiving therein the liquid suspension. a second chamber for receiving therein the filtrate, and a filter disposed in a fluid path therebetween. the filter comprising pores sizes so as to prevent passage therethrough of the biological components: introducing the liquid suspension into the first chamber: maintaining a pressure in the first chamber being no greater than approximately 2 bar; maintaining a pressure in the second chamber being lower than that of the first chamber: and harvesting the concentrated biological components: wherein a retentate is obtained in which the concentration of the biological components therewithin is increased. relative to the liquid suspension. by a factor of at least fifty.

Abstract: The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge and transmembrane domain (HTM-1), wherein the modified hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2. Cells expressing CAR with the modified HTM-1 domain disclosed herein are expected to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.

Abstract: Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.

Abstract: A bioreactor is provided, comprising a housing extending along a vertical axis and defining an internal cavity therewithin, top and bottom covers at opposite ends of the housing, and a plurality of ports, each configured to facilitate fluid communication between the internal cavity and the exterior of the bioreactor. The internal cavity has a frustoconical shape, the frustoconical shape being formed such that horizontal cross-sections are coaxial about a line which is angled with respect to the vertical axis.

Abstract: This disclosure is directed to new pharmaceutical compositions comprising ranpimase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.

Abstract: The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge domain, wherein the hinge domain comprises the amino acid sequence of SEQ ID NO:1. Cells expressing a CAR comprising the modified hinge domain disclosed herein are shown to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.

Abstract: This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.

Abstract: A cell-culture bioreactor operative to provide real-time reactor management in the fields of stir control, sparge control, and heat management responsively to wireless sensor feedback to optimize operating conditions to maximize cell-culture yield; and a bioreactor comprising: a vessel, having an open top; a headplate, configured to seal the vessel's open top; and a stirring device, comprising at least two independent stirring elements; wherein each of the stirring elements is configured to independently stir media accommodated within the vessel.

Abstract: Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.

Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.

Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.

Abstract: The present disclosure provides compositions and methods for providing a cell replacement therapy to treat various diseases, including pancreatic diseases and diabetes. Specifically, the disclosure provides three-dimensional (3D) cell clusters of transdifferentiated insulin producing cells attached to scaffolds, such as a polysaccharide matrix, in order to provide a cell replacement therapy.

Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.

Abstract: Provided an artificial bioxome particle comprising a cell membrane component and designed to undergo fusion with a target cell, wherein said bioxome particle is engineered to carry a cargo comprising at least one predetermined active molecule; and wherein said cargo can be released into the target cell after the fusion of the bioxome particle with the target cell; and wherein the cell membrane component is derived from a selected cellular or extracellular source; methods of use of the particles; and processes for manufacturing thereof.

Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.